Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

CB-839 in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 18.02.19
Views: 788
Rating:

Prof Funda Meric-Bernstam - MD Anderson Cancer Center, Houston, USA

Prof Funda Meric-Bernstam speaks to ecancer at the 2019 ASCO Genitourinary Cancers Symposium about a study looking at the combination of CB-839 with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer.

She explains that CB-839 was looked at in escalating doses, of 600mg and 800mg, and cabozantinib at the approved 60mg.

Prof Meric-Bernstam reports that the combination was safely delivered with the safety profile very similar to that of cabozantinib alone.

Related videos

follow us

Donate to ecancer


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation